Gem Pharmaceuticals announced today that the initial soft tissue sarcoma (STS) patients have been enrolled into the Company's Phase 2 clinical trial. This open-label study will assess the efficacy and ...

Against the backdrop of a case report, pembrolizumab was investigated as immunotherapy for undifferentiated pleomorphic soft tissue sarcoma. Noting that immunotherapy for soft tissue sarcoma (STS) has ...

This article first appeared with Targeted Oncology™. An orphan drug designation (ODD) was granted by the FDA to elraglusib for the treatment of patients with soft tissue sarcoma (STS). 1 Currently, a ...

Treatment with doxorubicin plus trabectedin (Yondelis), followed by trabectedin maintenance, improved overall survival (OS) and progression-free survival (PFS) in patients with metastatic or ...

Efti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the neoadjuvant setting in patients with soft tissue sarcoma Over three-fold increase in tumour ...

A novel intratumoral treatment was administered to the first patient in a phase 3 trial for certain patients with metastatic soft tissue sarcoma. A phase 3 trial for patients with metastatic soft ...

Prognostic factors in soft tissue sarcomas encompass a diverse spectrum of clinical, pathological and host-related parameters that influence patient outcomes. Increasingly, research is demonstrating ...

This retrospective cohort study of limb-sparing eSTS resections integrated clinical variables and radiomic features, including eSTS and limb dimensions. Target outcomes included surgical site ...

Kimberly Nix was well into her journey to become a doctor when life threw a wrench at her: She was diagnosed with metastatic sarcoma in 2021. At the time, Dr. Nix was only 28 years old and in the ...